PharmaTher to present at HC Wainwright Psychedelics


TORONTO, June 16, 2021 (GLOBE NEWSWIRE) – PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelic biotechnology company, announced, CEO, will make a presentation at the HC Wainwright Psychedelics in Psychiatry Virtual Conference and Beyond on June 17, 2021.

The corporate presentation will be available upon request starting at 7:00 a.m.ET. For more information about this event and to attend, visit:

As previously announced, the Company provided an update on its research and development initiatives, including the FDA’s phase 2 study with ketamine to treat Parkinson’s disease, a phase 2 study with KETABET â„¢ for resistant depression to treatment, and the development of new micro-needle patches to deliver psychedelics such as ketamine, psilocybin, DMT, MDMA and LSD.

For more information on PharmaTher’s business, visit

About PharmaTher Holdings Ltd.

PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) is a clinical-stage psychedelic biotechnology company focused on the research, development and commercialization of novel uses, formulations and delivery methods of psychedelics to treat mental health, neurological disorders and painful. . PharmaTher is currently conducting an FDA-approved Phase 2 clinical study with ketamine to treat Parkinson’s disease and is developing a new micro-needle patch for intradermal administration of psychedelics.
In addition to this, you will need to know more about it.
Learn more about: and follow us on Twitter and LinkedIn.

For more information about PharmaTher, please contact:

Fabio Chianelli
Chief executive officer
PharmaTher Holdings Ltd.
Phone. : 1-888-846-3171
Email: [email protected]

Neither the Canadian Securities Exchange nor its regulatory services provider has reviewed or accepted responsibility for the adequacy or accuracy of this release.


This press release contains “forward-looking information” within the meaning of applicable Canadian securities laws. These statements relate to future events or future performance. The use of any of the words “could”, “intention”, “expect”, “believe”, “will”, “projected”, “estimated”, “potential”, “objective” and Similar expressions and statements concerning which are not historical facts are intended to identify forward-looking information and are based on current beliefs or assumptions of PharmaTher Holdings Ltd. (the “Company”) as to the outcome and timing of such future events. Forward-looking information is based on reasonable assumptions that have been made by the Company on the date of information and is subject to known and unknown risks, uncertainties and other factors that may cause the results or events to be actuals differ materially from those anticipated in the forward-looking information. Given these risks, uncertainties and assumptions, you should not place undue reliance on these forward-looking statements. The forward-looking information contained in this press release is made as of the date hereof, and the Company is under no obligation to update or revise the forward-looking information, whether as a result of new information, future events. or otherwise, except as required by applicable securities laws. The foregoing statements expressly qualify any forward-looking information contained herein. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements are described under the heading “Risk Factors” in the Company’s Management’s Discussion and Analysis for the period February 28, 2021 (“MD&A”). , dated April 28. , 2021, which is available on the company profile at

This press release does not constitute an offer to sell or the solicitation of an offer to buy, and does not constitute an offer, solicitation or sale in any state, province, territory or jurisdiction in which such offering, soliciting or selling would be illegal prior to registration or qualification under the securities laws of any such state, province, territory or jurisdiction.


About Gloria Skelton

Check Also

CENTOGENE publishes its financial results for the first quarter of 2021 in

[ad_1] First quarter 2021 revenue of 65.0 million euros, driven by COVID-19 testing revenue, up …

Leave a Reply

Your email address will not be published.